SG
SGIOF.US Shionogi & Co. Ltd
- Market cap
- USD 16.5B
- P/E
- 10.8x
- P/B
- 1.51x
- ROE
- 13.6%
- Dividend yield
- 2.50%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is SGIOF.US undervalued?
Graham numberSGIOF.US trades 15.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shionogi & Co. Ltd fundamental analysis
No fundamental analysis for Shionogi & Co. Ltd yet.
Shionogi & Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shionogi & Co. Ltd
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and busines…
Full company profileShionogi & Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shionogi & Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 339B | 345B | 368B | 333B | 297B | 335B | 427B | 435B | 438B | 503B | 703B |
| Gross Profit | 261B | 271B | 309B | 277B | 245B | 280B | 364B | 377B | 374B | 414B | 514B |
| Operating Income | 108B | 115B | 145B | 131B | 117B | 110B | 149B | 153B | 157B | 162B | 198B |
| EBITDA | 139B | 157B | 188B | 175B | 159B | 143B | 242B | 223B | 231B | 190B | 282B |
| Net Income | 83.9B | 109B | 137B | 122B | 112B | 114B | 185B | 162B | 170B | 206B | 238B |
| EPS | 256 | 337 | 435 | 395 | 365 | 379 | 621 | 558 | 601 | 243 | 280 |
| Balance Sheet | |||||||||||
| Total Assets | 670B | 723B | 779B | 872B | 999B | 1.15T | 1.31T | 1.42T | 1.54T | 2.59T | 2.65T |
| Total Liabilities | 144B | 118B | 106B | 107B | 134B | 157B | 190B | 164B | 173B | 896B | 898B |
| Shareholders' Equity | 523B | 601B | 668B | 765B | 846B | 976B | 1.10T | 1.24T | 1.36T | 1.70T | 1.75T |
| Cash & Short-term Investments | 207B | 264B | 327B | 380B | 418B | 465B | 563B | 574B | 645B | 716B | 378B |
| Total Debt | 30.1B | 28.5B | 10.2B | 8.15B | 7.99B | 6.67B | 9.41B | 11.6B | 21.9B | 689B | 686B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 112B | 130B | 146B | 132B | 109B | 102B | 178B | 154B | 195B | 215B | 286B |
| Capital Expenditure | 23.3B | 17.0B | 9.12B | 11.8B | 32.9B | 31.6B | 37.2B | 28.3B | 52.1B | 14.6B | 21.6B |
| Free Cash Flow | 88.6B | 113B | 137B | 120B | 76.1B | 70.5B | 141B | 126B | 143B | 200B | 264B |
| Ratios | |||||||||||
| ROE | 16.0% | 18.1% | 20.5% | 16.0% | 13.2% | 11.7% | 16.8% | 13.1% | 12.5% | 12.2% | 13.6% |
| ROA | 12.5% | 15.1% | 17.6% | 14.0% | 11.2% | 9.9% | 14.1% | 11.4% | 11.1% | 8.0% | 9.0% |
| Net Profit Margin | 24.8% | 31.6% | 37.3% | 36.7% | 37.6% | 34.1% | 43.3% | 37.2% | 38.9% | 41.1% | 33.9% |
| Debt to Equity | 0.06x | 0.05x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x | 0.41x | 0.39x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shionogi & Co. Ltd dividends
- Dividend yield
- 2.50%
- Forward dividend
- 0.49 USD
- Payout ratio
- 27.4%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 56.5B | 66 | 27.4% |
| 2025 | JPY 48.7B | 172 | 28.6% |
| 2024 | JPY 43.9B | 151 | 27.1% |
| 2023 | JPY 36.1B | 121 | 19.5% |
| 2022 | JPY 33.1B | 110 | 29.0% |
| 2021 | JPY 32.5B | 106 | 29.1% |
| 2020 | JPY 31.1B | 101 | 25.5% |
| 2019 | JPY 27.6B | 88 | 20.1% |
| 2018 | JPY 24.2B | 75 | 22.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on Sep 27, 2024.
Who owns Shionogi & Co. Ltd
- Insiders 4.41%
- Institutions 60.50%
- Public & others 35.09%
- Shares outstanding 851M
- Free float 851M
Shionogi & Co. Ltd company profile
- Company name
- Shionogi & Co. Ltd
- Ticker
- SGIOF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 6,223
- Fiscal year end
- March
- Address
- Park Tower, Kita, Japan, 530-0011
- Phone
- 81 6 6202 2161
- Website
- shionogi.com
About Shionogi & Co. Ltd
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.
Shionogi & Co. Ltd management
10- Dr. Isao Teshirogi Ph.D.CEO, President & Representative Director · born 1959
- Dr. John Apeler Keller Ph.D.Senior Exec. Officer, SVP of R&D Supervisory Unit and Pharma. Tech. Research Div. & Director · born 1964
- Takuji FujiwaraAccounting & Finance Manager
- Mr. Takeshi Shiota Ph.D.Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.
- Mr. Yoshimasa KyokawaVice President of Corporate Communications & Secretary Office
- Yoshihiro FuruyaVice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office
- Mr. Kazuhiro HatanakaSenior Executive Officer & Senior VP of Corporate Supervisory Unit
- Akira Kato Ph.D.Senior Executive Officer & Senior VP of Supply Supervisory Unit
- Mr. Toshinobu Iwasaki Ph.D.Senior Executive Officer & Senior VP of Healthcare Business Supervisory Unit
- Masashi Deguchi Ph.D.Corporate Officer & Senior VP of Sustainability Management Division